Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 1999

View Archived Issues

Resveratrol inhibits HSV replication

Company Profile: ConjuChem

Endorex makes progress with vaccines and cancer therapies

Bristol-Myers Squibb and Genzyme Transgenics enter another agreement

Promising results seen in phase II/III lupus clinical trial

Chiron and Searle plan pivotal phase III trial for sepsis compound

Foscan NDA accepted for review

Avax Technologies and Neptunus execute joint venture agreement

Abgenix and Chiron enter autoimmune huMAb collaboration

Tissue-selective estrogenic compounds beneficial in bone and cardiovascular disorders

Antagonists of neuropeptide receptor in development at SB for obesity, sleep disorders

Fujisawa patents amide inhibitors of NO production

Adolor studies opioid antagonists for treatment of opiate-induced constipation

Targacept identifies potent nAChR antagonists

Wakunaga identifies potent and selective chymase inhibitor

Highly potent inhibitor of PDGF-induced SMC proliferation discovered at Japan Energy

Glaxo Wellcome's Zyban approved in The Netherlands for smoking cessation

FR-901469 derivatives synthesized and tested as antifungal agents at Fujisawa

Claims and counterclaims complicate Pfizer/Warner-Lambert/American Home Products triangle

Maret initiates clinical development of MARstem for chemotherapy-induced neutropenia

Rhodacyanine dye MKT-077 is a potential candidate antimalarial agent

Nasonex Nasal Spray approved for new pediatric indication in U.S.

Promising antidepressant and antiparkinsonian activity described for S-32504

Antidementia activity of geneserine derivative in preclinical studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...